GGrantIndex
Sort

11,323 grants matching glioblastoma

Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

$1,000,000
Evan Charles Unger · Nuvox Pharma, Llc · R44 · FY2022 · CA

TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO

$1,000,000
Ajit S Shah · Omniox, Inc. · R44 · FY2014 · CA

Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)

$1,000,000
Jon O Nagy · Nanovalent Pharmaceuticals, Inc. · R42 · FY2024 · CA

TUMOR RADIOSENSITIZATION USING A NITRIC-OXIDE-NEUTRAL, TUNABLE OXYGEN-BINDING PRO

$1,000,000
Ajit S Shah · Omniox, Inc. · R44 · FY2012 · CA

Tumor Antigen Targeted Nanoparticle Therapy for Glioblastoma (GBM)

$1,000,000
Jon O Nagy · Nanovalent Pharmaceuticals, Inc. · R42 · FY2025 · CA

Randomized Prospective Phase II Clinical Trial of NVX-108 in Association with Chemoradiation of Glioblastoma

$1,000,000
Evan Charles Unger · Nuvox Pharma, Llc · R44 · FY2017 · CA

Nanoparticle-based Sensitizer for Radiation Therapy of Glioblastoma

$1,000,000
Evan Charles Unger · Nuvox Pharma, Llc · R44 · FY2014 · CA

Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients

$999,999
Theresa Deisher · Avm Biotechnology, Llc · R44 · FY2022 · CA

Expedited Expansion Cohort Clinical Trial for Relapsed/Refractory 'no-option' Non-Hodgkin's Lymphoma/Leukemia Patients

$999,999
Theresa Deisher · Avm Biotechnology, Llc · R44 · FY2023 · CA

Targeting glioblastoma stem-like cells with custom-designed viral vectors

$999,999
Darin J Falk · Lacerta Therapeutics, Inc. · R42 · FY2020 · CA

Targeting glioblastoma stem-like cells with custom-designed viral vectors

$999,999
Darin J Falk · Lacerta Therapeutics, Inc. · R42 · FY2019 · CA

TAS::75 0849::TAS

$999,936
Paul West · Stemina Biomarker Discovery, Inc. · N44 · FY2010 · CA

Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma

$999,600
Wolfgang Oster · Oncoceutics, Inc. · R44 · FY2018 · CA

Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma

$999,600
Joshua E. Allen · Oncoceutics, Inc. · R44 · FY2019 · CA

CCR, LGI, Flow Cytometry Core

$999,466
Ferenc Livak · Division Of Basic Sciences - Nci · ZIC · FY2018 · CA

Tumor Monorail Device for Serial Glioblastoma Biopsy

$999,360
Sean Meehan · Exvade Bioscience, Inc. · R44 · FY2024 · CA

Adaptive Clinical Efficacy Evaluation of ONC201 in Recurrent High Grade Glioma

$999,250
Joshua E. Allen · Oncoceutics, Inc. · R44 · FY2020 · CA

NeuroAccess: a Focused Ultrasound System for SonoBiopsy of the Brain

$999,125
Bhaskar Ramamurthy · Cordance Medical, Inc. · R44 · FY2025 · CA

Development of Small Molecule Inhibitors and Biologic Agents for Treatment of Glioblastoma Using Intracerebral Microdialysis and Signatures of Vulnerability

$999,063
Jana Portnow · Beckman Research Institute/City Of Hope · U19 · FY2021 · CA

Tumor Monorail Device for Serial Glioblastoma Biopsy

$999,038
Sean Meehan · Exvade Bioscience, Inc. · R44 · FY2025 · CA

Single-cell Phosphoprotein Assay to Evaluate Brain Tumor Therapeutic Resistance

$999,016
Jing Zhou · Isoplexis, Inc. · R44 · FY2019 · CA

SBIR Phase II: Transcranial Dynamic Focused Ultrasound for the Non-Invasive Opening of the Blood-Brain Barrier (BBB)

$998,501
Bhaskar S Ramamurthy · Cordance Medical Inc. · · FY2021 · TIP

Spatial genomics analysis of tumor samples

$998,481
Kirsten Frieda · Spatial Genomics, Inc. · R44 · FY2024 · CA

Spatial genomics analysis of tumor samples

$998,481
Kirsten Frieda · Spatial Genomics, Inc. · R44 · FY2023 · CA

Molecular, Cellular, and Tissue Characterization Unit

$996,148
William E Gillanders · Washington University · U2C · FY2018 · CA